Nichols Weston 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
Crinetics (CRNX) Director Nichols Weston Receives Awards
What Happened
Nichols Weston, a director of Crinetics Pharmaceuticals (CRNX), received two equity awards on 2026-06-18: 5,925 restricted stock units (RSUs) and 9,730 derivative awards (stock options), each reported at $0.00 (no cash paid). The Form 4 reports these as grants (transaction code A); the filing does not state a cash value or exercise price for the derivative award.
Key Details
- Transaction date: 2026-06-18; Form 4 filed: 2026-06-22 (filed within the SEC’s two-business-day window given the June 19 holiday/weekend).
- Awards: 5,925 RSUs (F1) and 9,730 derivative awards (stock option-type award; F2), both reported at $0.00.
- Vesting: RSUs vest 100% on the earlier of (a) the first anniversary of the grant or (b) the next annual meeting of stockholders, subject to continued board service (F1). The derivative award vests/becomes exercisable on the same timing and service condition (F2).
- Shares owned after transaction: not specified in the provided excerpt.
- Transaction code: A = Award/Grant. No 10b5-1 plan or tax-withholding details reported in the excerpt.
Context
RSUs represent a right to receive shares upon vesting; stock options give the right to purchase shares after vesting. These are compensation grants to a director and are routine governance/compensation activity rather than an open-market purchase or sale. They do not by themselves indicate immediate buying or selling of stock.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-18+5,925→ 22,225 total - Award
Stock Option (Right to Buy)
[F2]2026-06-18+9,730→ 9,730 totalExercise: $35.87Exp: 2036-06-18→ Common Stock (9,730 underlying)
Footnotes (2)
- [F1]The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
- [F2]The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.